WO2009132353A3 - Differential diagnosis of prostate cancer and benign prostate disease - Google Patents

Differential diagnosis of prostate cancer and benign prostate disease Download PDF

Info

Publication number
WO2009132353A3
WO2009132353A3 PCT/US2009/041837 US2009041837W WO2009132353A3 WO 2009132353 A3 WO2009132353 A3 WO 2009132353A3 US 2009041837 W US2009041837 W US 2009041837W WO 2009132353 A3 WO2009132353 A3 WO 2009132353A3
Authority
WO
WIPO (PCT)
Prior art keywords
prostate
differential diagnosis
prostate cancer
disease
benign
Prior art date
Application number
PCT/US2009/041837
Other languages
French (fr)
Other versions
WO2009132353A2 (en
Inventor
Seon-Joo Yoon
Senitiroh Hakomori
Original Assignee
The Biomembrane Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Biomembrane Institute filed Critical The Biomembrane Institute
Publication of WO2009132353A2 publication Critical patent/WO2009132353A2/en
Publication of WO2009132353A3 publication Critical patent/WO2009132353A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4724—Lectins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)

Abstract

A diagnostic assay that distinguishes prostate cancer is described. The assay can distinguish prostate cancer from benign prostate disease.
PCT/US2009/041837 2008-04-26 2009-04-27 Differential diagnosis of prostate cancer and benign prostate disease WO2009132353A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4817208P 2008-04-26 2008-04-26
US61/048,172 2008-04-26

Publications (2)

Publication Number Publication Date
WO2009132353A2 WO2009132353A2 (en) 2009-10-29
WO2009132353A3 true WO2009132353A3 (en) 2010-02-18

Family

ID=41217453

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/041837 WO2009132353A2 (en) 2008-04-26 2009-04-27 Differential diagnosis of prostate cancer and benign prostate disease

Country Status (1)

Country Link
WO (1) WO2009132353A2 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007120478A2 (en) * 2006-04-03 2007-10-25 Massachusetts Institute Of Technology Glycomic patterns for the detection of disease

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007120478A2 (en) * 2006-04-03 2007-10-25 Massachusetts Institute Of Technology Glycomic patterns for the detection of disease

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CUMMINGS, R.D. ET AL.: "Characterization of the structural determinants required for the high affinity interaction of asparagine-linked oligosaccharides with immobilized Phaseolus vulgaris leukoagglutinating and erythroagglutinating lectins", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 257, no. 19, 10 October 1982 (1982-10-10), pages 11230 - 11234 *
FUJIMURA, T. ET AL.: "Glycosylation status of haptoglobin in sera of patients with prostate cancer vs. benign prostate disease or normal subjects", INTERNATIONAL JOURNAL OF CANCER, vol. 122, no. ISS.1, 5 September 2007 (2007-09-05), pages 39 - 49, Retrieved from the Internet <URL:http://www3.interscience.wiley.com/journal/116312564/abstract> *
GRAVEL, P.: "Identification of Glycoproteins on Nitrocellulose Membranes Using Lectin Blotting", THE PROTEIN PROTOCOLS HANDBOOK, 2002, pages 779 - 793 *
TABARES, G. ET AL.: "Different glycan structures in prostate-specific antigen from prostate cancer sera in relation to seminal plasm PSA", GLYCOBIOLOGY, vol. 16, no. 2, 2006, pages 132 - 145 *
TAGUCHI, T. ET AL.: "Proton NMR study oftriantennary complex type N-lined glycan chains: assignment of proton chemical shifts of the 13 -Man residue in a basic unit of the triantennary glycan chain having a Glc NAc beta1? 6Man alpha1 ? 6Manbeta ? sequence", GLYCOBIOLOGY, vol. 7, no. 1, 1997, pages 31 - 36 *

Also Published As

Publication number Publication date
WO2009132353A2 (en) 2009-10-29

Similar Documents

Publication Publication Date Title
WO2010017515A3 (en) Breast cancer specific markers and methods of use
WO2009029266A3 (en) Diagnostic tool for diagnosing benign versus malignant thyroid lesions
WO2008153615A3 (en) Preparing carbohydrate microarrays and conjugated nanoparticles
WO2010135692A3 (en) Mirna biomarkers of prostate disease
WO2008008430A3 (en) Micro-rna-based methods and compositions for the diagnosis and treatment of colon cancer-related diseases
WO2011037643A3 (en) Compositions and methods for detecting and treating prostate carcinoma
WO2008153705A3 (en) Methods of treating, diagnosing and detecting fgf21-associated disorders
WO2006085249A3 (en) Analysis of pulmonary nodules from ct scans using the contrast agent enhancement as a function of distance to the boundary of the nodule
WO2008060363A8 (en) Tumor associated markers in the diagnosis of prostate cancer
EP2041569A4 (en) Lung cancer diagnostic assay
PL1858929T3 (en) Diagnosis of prostate cancer
WO2008022263A3 (en) Methods for lymph system imaging
WO2009132353A3 (en) Differential diagnosis of prostate cancer and benign prostate disease
WO2010144846A3 (en) Gastrointestinal disease or disorder imaging and treatment
WO2006114611A3 (en) Materials and methods relating to the diagnosis of cancer
WO2008030559A3 (en) Methods, compositions, and kits for the detection and monitoring of colon cancer
WO2007114954A3 (en) Methods, compositions, and kits for the detection and monitoring of kidney cancer
AU2006902544A0 (en) Diagnosis, prognosis and treatment of neurodegenerative disease XXIII
AU2006902940A0 (en) Diagnostic and prognostic indicators of cancer
AU2007901680A0 (en) Diagnosis, prognosis and treatment of neurodegenerative disease VII
AU2006902541A0 (en) Diagnosis, prognosis and treatment of neurodegenerative disease XXV
AU2008901529A0 (en) Diagnosis, prognosis and treatment of neurodegenerative disease VII
AU2006902547A0 (en) Diagnosis, prognosis and treatment of neurodegenerative disease XX
AU2006902529A0 (en) Diagnosis, prognosis and treatment of neurodegenerative disease XIV
AU2006901701A0 (en) Diagnosis, prognosis and treatment of neurodegenerative disease III

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09736028

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09736028

Country of ref document: EP

Kind code of ref document: A2